Literature DB >> 9688544

Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.

K N Dzhandzhugazyan1, A F Kirkin, P thor Straten, J Zeuthen.   

Abstract

Ecto-ATPase activities of melanocytes and human melanoma cell lines differing in the stage of progression were compared. A dramatic increase in ecto-ATPase activity above the level of normal melanocytes was demonstrated in the differentiated melanomas and was followed by a gradual decrease with tumor progression. The characteristics of this enzymatic activity were consistent with CD39/ecto-ATP diphosphohydrolase (ATPDase) which was found to be the major ecto-ATP-hydrolysing enzyme in melanomas. Indeed, the expression of CD39 and the level of CD39 mRNA followed a similar pattern. Since CD39 is known to regulate homotypic adhesion and, supposedly, affects the disaggregation step, we suggest that overexpression of CD39 may enable tumor cells to reduce contacts with T-lymphocytes and escape from immunological recognition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688544     DOI: 10.1016/s0014-5793(98)00603-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.

Authors:  Qiang Wei; Stefano Costanzi; Qiu-Zhen Liu; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2011-05-23       Impact factor: 5.858

2.  Diminution in adenine nucleotide hydrolysis by platelets and serum from rats submitted to Walker 256 tumour.

Authors:  Andréia Buffon; Vanessa B Ribeiro; Alessandra S Schanoski; João J F Sarkis
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

Review 3.  Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

Authors:  Magis Mandapathil; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2011-06-26       Impact factor: 4.388

Review 4.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

5.  The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice.

Authors:  Jing-Hui Chong; Guo-Guang Zheng; Yuan-Yuan Ma; Hai-Yan Zhang; Kun Nie; Yong-Min Lin; Ke-Fu Wu
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

6.  Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.

Authors:  Sebastian Fm Häusler; Itsaso Montalbán Del Barrio; Joachim Diessner; Roland G Stein; Jenny Strohschein; Arnd Hönig; Johannes Dietl; Jörg Wischhusen
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

Review 7.  The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Authors:  T L Whiteside; M Mandapathil; P Schuler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  Ecto-ATPase activity on the surface of Trypanosoma cruzi and its possible role in the parasite-host cell interaction.

Authors:  Danielle F R Bisaggio; Carlos Eduardo Peres-Sampaio; José Roberto Meyer-Fernandes; Thaïs Souto-Padrón
Journal:  Parasitol Res       Date:  2003-08-22       Impact factor: 2.289

Review 9.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

10.  Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Authors:  Magis Mandapathil; Miroslaw J Szczepanski; Marta Szajnik; Jin Ren; Diana E Lenzner; Edwin K Jackson; Elieser Gorelik; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.